Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:DCPH

Deciphera Pharmaceuticals (DCPH) Stock Price, News & Analysis

Deciphera Pharmaceuticals logo

About Deciphera Pharmaceuticals Stock (NASDAQ:DCPH)

Advanced Chart

Key Stats

Today's Range
$25.59
$25.59
50-Day Range
$25.55
$25.59
52-Week Range
$9.90
$25.61
Volume
600 shs
Average Volume
1.29 million shs
Market Capitalization
$2.21 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Deciphera Pharmaceuticals, Inc., a biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response to existing cancer therapies in the United States and internationally. Its lead drug candidate is QINLOCK used for the treatment of gastrointestinal stromal tumors (GIST), as well as in INTRIGUE Phase 3 study to treat second-line GIST. The company is also developing vimseltinib, an orally administered, potent, and highly selective switch-control kinase inhibitor of colony stimulating factor 1 receptor (CSF1R) for the treatment of tenosynovial giant cell tumor (TGCT); and DCC-3116 to treat RAS/RAF mutant cancers that is in the preclinical-stage. Deciphera Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Waltham, Massachusetts.

Receive DCPH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Deciphera Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

DCPH Stock News Headlines

Trump Makes Major Crypto Announcement
Trump's Pro-Crypto Agenda Finally Sparks Market Recovery With Bitcoin surging past $90,000 and altcoins heating up, I'm seeing all the signs of a major market shift For a limited time, I'm revealing the name and complete analysis behind my top Trump-era crypto pick.
See More Headlines

DCPH Stock Analysis - Frequently Asked Questions

Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) posted its quarterly earnings data on Tuesday, February, 6th. The company reported ($0.54) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.58) by $0.04. The company's revenue for the quarter was up 32.9% compared to the same quarter last year.
Read the conference call transcript
.

Deciphera Pharmaceuticals (DCPH) raised $101 million in an initial public offering on Thursday, September 28th 2017. The company issued 6,300,000 shares at $15.00-$17.00 per share. J.P. Morgan and Piper Jaffray served as the underwriters for the IPO and JMP Securities and Nomura were co-managers.

Based on aggregate information from My MarketBeat watchlists, some other companies that Deciphera Pharmaceuticals investors own include NVIDIA (NVDA), Meta Platforms (META), Tesla (TSLA), Netflix (NFLX), Advanced Micro Devices (AMD), JPMorgan Chase & Co. (JPM) and Alphabet (GOOG).

Company Calendar

Last Earnings
2/06/2024
Today
5/04/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:DCPH
Fax
N/A
Employees
300
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-194,940,000.00
Net Margins
-108.86%
Pretax Margin
-108.62%

Debt

Sales & Book Value

Annual Sales
$174.91 million
Price / Cash Flow
N/A
Book Value
$4.38 per share
Price / Book
5.84

Miscellaneous

Free Float
82,438,000
Market Cap
$2.21 billion
Optionable
Optionable
Beta
0.19
A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for May 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

This page (NASDAQ:DCPH) was last updated on 5/4/2025 by MarketBeat.com Staff
From Our Partners